The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan ...

Sarepta Therapeutics shares traded lower in premarket trade on Tuesday, as the drugmaker relented to a Food and Drug ...

Sarepta Therapeutics ( NASDAQ: SRPT) faces an “arduous and treacherous path” to bring its gene therapy Elevidys back to market, according to a STAT report citing a senior FDA official, suggesting the ...

Sarepta Therapeutics has rejected a call by the Food and Drug Administration to stop shipments of its muscular dystrophy drug.

The company agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular dystrophy.

Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...

Mega-Cap Movers (Market Cap $200B+): Large-Cap Stock Movers (Market Cap $10B-$200B): New Providence Acquisition Corp N (ASTS): +8.77% CoreWeave (CRWV): CoreWeave stock initiated with Reduce rating by ...

Learn about the executive team and board of directors at Sarepta Therapeutics Inc (1SRPT:XMIL) and review their bios and compensation over the latest fiscal years.

Consolidation of Webull Pay Positions Webull Corp for Q3 Reintroduction of Crypto Trading on Webull Platform in the United ...